Repro Novo's co-founders invested their own money for the costly process of finding and negotiating assets. This allowed them to secure a promising candidate before approaching institutional investors, demonstrating strong conviction and de-risking the initial investment for VCs.
Related Insights
To win the best pre-seed deals, investors should engage high-potential talent during their 'founder curious' phase, long before a formal fundraise. The real competition is guiding them toward conviction on their own timeline, not battling other VCs for a term sheet later.
Despite operating in the popular women's health space, Repro Novo's CEO advises founders to pitch investors on tangible commercial opportunities and critical unmet needs. This focus on market gaps and pricing potential is more compelling than simply relying on a sector-specific trend for funding.
Instead of hoarding early capital, Actuate's CEO synthesized a kilogram of their molecule and sent it to labs worldwide. The goal was to fail fast by seeing if promising results could be replicated, a crucial de-risking step before committing larger funds.
ProKidney's significant funding from co-founder Pablo Legorreta and investor Carlos Slim was driven by their direct family experiences with kidney disease. This shows that for high-risk, long-term biotech ventures, a deep personal connection to the mission can be a more powerful motivator for investors than purely financial interest.
To maintain product focus and avoid the 'raising money game,' the founders of Cues established a separate trading company. They used the profits from this successful venture to self-fund their AI startup, enabling them to build patiently without being beholden to VC timelines or expectations.
The initial capital for a new fund-of-funds doesn't come from cold outreach to institutions. The process mirrors an emerging VC's first fundraise, relying on a personal network of operators, VCs, and high-net-worth individuals who already believe in the founder. The strategy is to work the existing network outward, not pitch institutions from day one.
Despite a $50 million exit from their previous company, the Everflow founders intentionally limited their initial investment to a few hundred thousand dollars and didn't take salaries for two years. They believed capital scarcity forces focus and efficiency, preventing wasteful spending while they were still figuring out the product.
When founders invest their own money, it signals an unparalleled level of commitment and belief. This act serves as a powerful 'magnetic pull,' de-risking the opportunity in the eyes of external investors and making them significantly more likely to commit their own capital.
The company adopted a phased approach, using initial seed funding to de-risk the program by focusing narrowly on manufacturing (CMC) and regulatory hurdles to clear its IND. This milestone-driven strategy made it a more attractive investment for a larger Series A intended to fund clinical trials.
Founders Fund's perk allowing employees to co-invest personally is a clever mechanism to test true conviction. If an investor sponsoring a deal is unwilling to put their own money in, it raises a serious question about their belief in the investment's potential, forcing them to justify why it's a better allocation for LPs than their own capital.
